Moreover, preclinical studies using combined treatment of Zibotentan and the EGFR inhibitor gefitinib suppressed proliferation, invasion, and vascular endothelial growth factor (VEGF) production in ovarian cancer cells [13]. The gene discussed is VEGFA; the disease is ovarian carcinoma.